Syndax Pharmaceuticals (NASDAQ: SNDX) is one of 45 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it contrast to its competitors? We will compare Syndax Pharmaceuticals to similar companies based on the strength of its analyst recommendations, institutional ownership, dividends, risk, earnings, valuation and profitability.
Risk and Volatility
Syndax Pharmaceuticals has a beta of 4.69, meaning that its stock price is 369% more volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals’ competitors have a beta of 1.28, meaning that their average stock price is 28% more volatile than the S&P 500.
This table compares Syndax Pharmaceuticals and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Syndax Pharmaceuticals||$1.22 million||-$53.19 million||-4.15|
|Syndax Pharmaceuticals Competitors||$579.30 million||$241.72 million||-6.54|
Syndax Pharmaceuticals’ competitors have higher revenue and earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of current recommendations and price targets for Syndax Pharmaceuticals and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Syndax Pharmaceuticals Competitors||116||752||1614||58||2.64|
Syndax Pharmaceuticals presently has a consensus target price of $24.29, suggesting a potential upside of 106.16%. As a group, “Biopharmaceuticals” companies have a potential upside of 4.97%. Given Syndax Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts plainly believe Syndax Pharmaceuticals is more favorable than its competitors.
This table compares Syndax Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Syndax Pharmaceuticals Competitors||-13,404.97%||246.04%||-20.09%|
Institutional & Insider Ownership
70.7% of Syndax Pharmaceuticals shares are held by institutional investors. Comparatively, 45.2% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 24.1% of Syndax Pharmaceuticals shares are held by insiders. Comparatively, 14.9% of shares of all “Biopharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Syndax Pharmaceuticals beats its competitors on 7 of the 12 factors compared.
Syndax Pharmaceuticals Company Profile
Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer. It is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body’s immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase Ib/II clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer.
What are top analysts saying about Syndax Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Syndax Pharmaceuticals Inc. and related companies.